Phibro Animal Health Corporation's stock surged 9.78% in after-hours trading following the release of its second-quarter financial results, which significantly exceeded analyst expectations.
The company reported adjusted earnings per share of $0.87 for the quarter, beating the consensus estimate of $0.67 by 29.85%. Quarterly sales reached $373.9 million, surpassing estimates of $355.637 million by 5.14% and representing a 20.89% increase compared to the same period last year.
Furthermore, Phibro Animal Health raised its financial guidance for fiscal year 2026, now projecting net sales between $1.45 billion and $1.50 billion and adjusted EBITDA between $245 million and $255 million. The strong performance was attributed to faster-than-expected uptake of the newly integrated MFA portfolio and sustained growth in nutritional specialty and vaccine offerings across key markets.